- Beijing Tiantan reported a net income of 632.6 million yuan for the first half of the year.
- The company generated a total revenue of 3.11 billion yuan during the same period.
- Investment analysts have given 10 buy recommendations for Beijing Tiantan’s stock, with 1 hold recommendation and no sell recommendations.
A look at Beijing Tiantan Biological Products Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Beijing Tiantan Biological Products, a company specializing in biological products, has received promising Smartkarma Smart Scores for its long-term outlook. With a Growth score of 5 and a Resilience score of 4, the company is well-positioned for future expansion and demonstrates a strong ability to withstand market challenges. These high scores indicate potential for sustained growth and a solid foundation for navigating uncertainties.
Additionally, Beijing Tiantan Biological Products maintains average scores in Value, Dividend, and Momentum, showcasing a balanced performance across key factors. This suggests a steady investment choice with a competitive edge in the biological products sector. Overall, the company’s focus on researching, developing, and commercializing biological products, particularly for hepatitis treatment and vaccine products, underscores its commitment to advancing healthcare solutions.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
